Bristol-Myers Pays $2.1B For Heart Failure Drug Co.
New York-based Bristol-Myers said on Monday that it is paying about $2.07 billion to acquire Cardioxyl Pharmaceuticals, a biotechnology company specializing in drugs that treat heart failure....To view the full article, register now.
Already a subscriber? Click here to view full article